Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention

To evaluate the safety and efficacy of switching to bivalirudin during primary percutaneous coronary intervention (PCI) for patients who received preprocedure unfractionated heparin (UFH).

[1]  C. Held,et al.  Bivalirudin versus Heparin Monotherapy in Myocardial Infarction , 2017, The New England journal of medicine.

[2]  S. Windecker,et al.  Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial , 2016, British Medical Journal.

[3]  P. Shekelle,et al.  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2016, British Medical Journal.

[4]  Shrikant Pawar.  Cross-cultural adaptation of self-report measures , 2015 .

[5]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[6]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[7]  Chris Cameron,et al.  A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL , 2014, Systematic Reviews.

[8]  H. Schunkert,et al.  Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. , 2014, European heart journal.

[9]  K. Huber,et al.  Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial , 2014, European heart journal.

[10]  S. Pocock,et al.  Bivalirudin started during emergency transport for primary PCI. , 2013, The New England journal of medicine.

[11]  Andrea Cipriani,et al.  Conceptual and Technical Challenges in Network Meta-analysis , 2013, Annals of Internal Medicine.

[12]  S. Mehta,et al.  Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). , 2013, Journal of interventional cardiology.

[13]  J. Messenger,et al.  Clinical ResearchInterventional CardiologyThe Prevalence and Outcomes of Transradial Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Analysis From the National Cardiovascular Data Registry (2007 to 2011) , 2013 .

[14]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[15]  A. Raval,et al.  Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus , 2012, Journal of Thrombosis and Thrombolysis.

[16]  M. Samama,et al.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[17]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[18]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[19]  Isabelle Boutron,et al.  Single-Center Trials Show Larger Treatment Effects Than Multicenter Trials: Evidence From a Meta-epidemiologic Study , 2011, Annals of Internal Medicine.

[20]  H. White,et al.  Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. , 2011, Journal of the American College of Cardiology.

[21]  G. Stone,et al.  Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction , 2011, Circulation.

[22]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[23]  S. Pocock,et al.  Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. , 2008, Journal of the American College of Cardiology.

[24]  S. Murphy,et al.  Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). , 2007, The American journal of cardiology.

[25]  K. Kent,et al.  Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. , 2006, The Journal of invasive cardiology.

[26]  R. Califf,et al.  Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. , 2004, JAMA.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[29]  K. Matin,et al.  An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. , 2016, American heart journal.

[30]  Jeroen J. Bax,et al.  [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.